Despite reported slowing of progression, regulators said the evidence on the novel oral agent blarcamesine did not support a positive benefit-risk balance.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/ema-rejects-alzheimers-drug-after-trial-falls-short-2025a1000yz0?src=rss
Author :
Publish date : 2025-12-12 17:12:00
Copyright for syndicated content belongs to the linked Source.
